DE LUCA, Giovanna
 Distribuzione geografica
Continente #
NA - Nord America 2.945
EU - Europa 2.404
AS - Asia 1.846
SA - Sud America 184
AF - Africa 11
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 1
Totale 7.401
Nazione #
US - Stati Uniti d'America 2.922
SG - Singapore 721
CN - Cina 580
UA - Ucraina 450
IE - Irlanda 435
GB - Regno Unito 346
TR - Turchia 340
SE - Svezia 279
DE - Germania 222
IT - Italia 212
FR - Francia 199
BR - Brasile 168
FI - Finlandia 125
IN - India 94
RU - Federazione Russa 76
VN - Vietnam 40
CA - Canada 20
CZ - Repubblica Ceca 16
HK - Hong Kong 14
IR - Iran 10
BE - Belgio 9
EU - Europa 9
PL - Polonia 9
AR - Argentina 8
BD - Bangladesh 8
ZA - Sudafrica 7
CH - Svizzera 6
IL - Israele 6
IQ - Iraq 6
GR - Grecia 4
KZ - Kazakistan 4
UZ - Uzbekistan 4
AT - Austria 3
JP - Giappone 3
LT - Lituania 3
MX - Messico 3
RS - Serbia 3
UY - Uruguay 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
CL - Cile 2
EC - Ecuador 2
ES - Italia 2
ID - Indonesia 2
MA - Marocco 2
NP - Nepal 2
PK - Pakistan 2
AM - Armenia 1
AU - Australia 1
BG - Bulgaria 1
DK - Danimarca 1
EG - Egitto 1
ET - Etiopia 1
IM - Isola di Man 1
JO - Giordania 1
KR - Corea 1
LB - Libano 1
NL - Olanda 1
PH - Filippine 1
RO - Romania 1
TJ - Tagikistan 1
VE - Venezuela 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 7.401
Città #
Singapore 577
Jacksonville 511
Chandler 508
Dublin 431
Southend 258
Izmir 192
Princeton 188
Nanjing 151
Wilmington 128
Ashburn 112
The Dalles 100
Beijing 99
Santa Clara 95
Cambridge 84
Dearborn 84
Munich 61
Tongling 59
Nanchang 58
Ann Arbor 51
Woodbridge 51
New York 48
Altamura 45
Chieti 34
Dong Ket 33
Los Angeles 32
Jiaxing 29
Houston 26
Boardman 25
Shenyang 25
Helsinki 24
Norwalk 24
Tianjin 20
Grevenbroich 19
Kunming 19
Turku 18
Washington 17
Hebei 16
Frankfurt am Main 15
São Paulo 15
London 14
Hong Kong 13
Brno 12
Changsha 12
Hangzhou 12
Leawood 12
San Mateo 12
Ardabil 10
Nuremberg 10
Augusta 9
Brooklyn 9
Cedar Knolls 9
Dallas 9
Jinan 9
Torino 9
Toronto 9
Brussels 8
Guangzhou 8
Lanzhou 8
Pescara 8
Teramo 8
Campobasso 7
Monmouth Junction 7
Warsaw 7
Falls Church 6
Fribourg 6
Montesilvano Marina 6
Ningbo 6
Changchun 5
Hanover 5
Joinville 5
Orange 5
Rio de Janeiro 5
Rome 5
Roubaix 5
San Francisco 5
Stockholm 5
Taizhou 5
Zhengzhou 5
Ankara 4
Boston 4
Brasília 4
Johannesburg 4
Olomouc 4
Phoenix 4
San Vito Chietino 4
Tashkent 4
Belgrade 3
Belo Horizonte 3
Borgomanero 3
Charlotte 3
Chicago 3
Curitiba 3
Düsseldorf 3
Florence 3
Milan 3
Montreal 3
Mumbai 3
Oxford 3
Pelotas 3
Pianella 3
Totale 4.666
Nome #
Integrated Lipidomics and Metabolomics Analysis of Tears in Multiple Sclerosis: An Insight into Diagnostic Potential of Lacrimal Fluid 138
IL 13 in multiple sclerosis 134
Alzheimer patients treated with an AchE inhibitor show higher IL-4 and lower IL-1β levels and expression in peripheral blood mononuclear cells 127
Increasing age at disability milestones among MS patients in the MSBase Registry 110
The Multiple Sclerosis Knowledge Questionnaire: a self administered instrument for recently diagnosed patients 109
Effetti sinergici della terapia con interferone-beta sulla attivazione, adesione ed apoptosi linfocitaria nella sclerosi multipla esacerbante/remittente 106
Chemokines are Modulated by Interferon beta 1B (IFNT-Beta IB) in Relapsing-Remitting Multiple Sclerosis (RR-MS) 104
La funzione soppressoria è ridotta nella polineuropatia demielinizzante cronica infiammatoria (CIDP) 102
Anti-glycolipid and anti-tubulin antibodies in chronic inflammatory demyelinating polyneuropathy 102
Acetylcholine in multiple sclerosis: possible involvement in the modulation of the immune response and in oligodendrocyte recruitment. 101
Rantes Levels and mRNA Expression in Relapsing-Remitting Multiple Sclerosis (RR-MS): Effect of interferon Beta 1b (IFNBeta 1b) Treatment 100
The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry. 99
Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis 98
Lipidomic investigations for the characterization of circulating serum lipids in multiple sclerosis 97
Interferon β1b modulates MCP-1 expression and production in relapsing-remitting multiple sclerosis 97
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone 96
Dysimmune demyelinating polyneuropathies: expression of adhesion molecules in sural nerves and changes in cellular immunity (suppressor cell function and cytokine mRNA expression) induced by treatment (progetto presentato a Telethon) 95
Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines. 94
Chemokine production by mononuclear cells from relapsing-remitting multiple sclerosis (RR-MS) patients 94
Effetti sinergici della terapia con interferone-beta sulla attivazione. Adesione ed apoptosi linfocitaria nella sclerosi multipla esacerbante /remittente. (C22) 93
Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. 93
Convulsive status epilepticus due to new encephalic demyelinating lesions in multiple sclerosis 93
Effect of TNF intraneural injection into the rat sciatic nerve 92
Rantes and MCP-1 Secretion by Mononuclear Cells of Patients with Nultiple Sclerosis 92
Prednisone and plasma exchange improve suppressor cell function in chronic inflammatory demyelinating polyneuropathy. 92
The Chieti experience with Interferon B1b (IFNB1b) during the first 2 years: side effects. 91
MCP-1 expression and secretion in adherent monocyte cultures from multiple sclerosis patients treated with interferon beta-1b 91
Anti-JCV serostatus, index value and clinical features in patients affected by multiple sclerosis. 91
The Chieti Experience with interferon B1b (IFNB1b) during the first 2 years: Efficacy 89
Interferon beta normalizes suppressor cell function in dysimmune neuropathies. 89
Plasma exchange and prednisone improve suppressor cell function in dysimmune neuropathies 88
Effect of the disclosure of MS diagnosis on anxiety, mood and quality of life of patients: a prospective study 88
Interferon beta1b: the Chieti experience 87
Effects of IL10 on recombinant interferon-beta1b stimulated suppressor cell function in MS and controls subjects 86
Effect of rhTNF-alpha injection into rat sciatic nerve 86
Interferon beta normalizes suppressor cell function in dysimmune neuropathies 85
A difficult pediatric case: ADEM evolving in multiple sclerosis complicated by progressive multifocal leukoencephalopathy after Natalizumab treatment. 85
Serum soluble adhesion molecules and proinflammatory cytokines are not increased in chronic inflammatory demyelinating polyneuropathy 84
OXIDATIVE MODIFICATIONS OF CEREBRAL TRANSTHYRETIN ARE ASSOCIATED WITH MULTIPLE SCLEROSIS 84
rlFN-beta-1B stimulated suppressor cell function in multiple sclerosis: effects of anti-IL-10 monoclonal antibody 83
JCV-Ab serostatus in MS patients treated with Natalizumab 83
Natalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy. 83
Development and validation of a patient self-assessed questionnaire on satisfaction with communication of the multiple sclerosis diagnosis. 83
An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care. 83
Nail loss after teriflunomide treatment: a new potential adverse event 83
Breastfeeding is not related to postpartum relapses in multiple sclerosis. 82
Low dose oral methotrexate (MTX) in chronic progressive (CP) multiple sclerosis (MS) 82
Real-life impact of early interferon beta therapy in relapsing multiple sclerosis 81
Shared T Cell Receptor Usage of Cerebrospinal Fluid Cells in Familial Multiple Sclerosis da: X° National A.I.N.I. Congress Association Italiana Neuroimmunologia - Florence, Italy, November 15/16,1999 80
Prevalence of JC virus antibodies in human serum and seroconversion rate with first-generation and second generation ELISA: the novel assay improves specificity andsensitivity to detect anti-JC virus antibodies 79
Neuropsychological testing and quantitative electroencephalography: a search of neurophysiological markers of cognitive decline in multiple sclerosis 78
Proteomic investigations on differential post-translational modification of transthyretin in multiple sclerosis. 78
Multiphasic Adem or Multiple Sclerosis? Treatement implications. 77
CD1A and CD1E gene polymorphisms are associated withsusceptibility to multiple sclerosis 76
A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy 76
Livelli sierici e liquorali di IL13 nella Sclerosi Multipla 75
Effect of rhTNF-a injection into rat sciatic nerve 75
Progressive multifocal leukoencephalopathy associated with natalizumab in paediatric multiple sclerosis 75
Mononeuropathy following subcutaneous interferon-β injection 74
Contribution of metabolomics to multiple sclerosis diagnosis, prognosis and treatment 74
Plasma exchange and prednisone improve suppressor cell function in dysimmune neuropathies 73
Patient adherence to and tolerability of self-administered interferon beta-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study 73
Interferon β 1b: The Chieti experience 72
Treatment discontinuation issues in fingolimod treated patients: the Chieti experience. 72
IL-13 levels in serum and cerebro-spinal fluid of multiple sclerosis patients 70
Neuropsychological testing and event-related potentials: markers of cognitive impairment in patients with multiple sclerosis 70
Suppressor cell function is decreased in chronic inflammatory demyelinating polyneuropathy 69
Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica. 69
Interferone beta1b: bilancio su un gruppo di 30 pazienti 68
Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register 68
Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis 66
Evaluation of suppressor cell function in chronicn inflammatory demyelinating polyneuropathy (CIDP) 64
Non-neuronal acetylcholine: a new modulator of immune responses in multiple sclerosis patients. 64
Effects of IFN-Beta on rantes and MCP-1 secretion by mononuclear cells frm patients with multiple sclerosis 63
A Multicentre italian study on efficacy and safety of Glatiramer Acetate in multiple sclerosis patients with allergic respiratory diseases 62
Interferon beta normalizes suppressor cell function in dysimmune neuropathies 61
Epilepsy and multiple sclerosis: Clinical, radiological, electrophysiological and neuropsychological aspects 60
Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients. 60
Gestione degli effetti indesiderati della terapia con interferone beta nella sclerosi multipla 59
Spinal cord injury in a patient with multiple sclerosis (MS) with secondary hydromyelia 57
Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs 56
Pregnancy and fetal outcomes after paternal exposure to disease modifying drugs for multiple sclerosis 56
Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study 55
Case Report: Multiple Sclerosis Relapses After Vaccination Against SARS-CoV2: A Series of Clinical Cases 54
Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society 53
Relation between Pro-inflammatory Cytokines and Acetylcholine Levels in Relapsing-Remitting Multiple Sclerosis Patients 51
Modulation of the immune response in multiple sclerosis patients: effect of non-neuronal acetylcholine 48
Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. 48
Plasma exchange and prednisone improve suppressor cell function in dysimmune neuropathies 46
mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis 46
Efficacy and safety of glatiramer acetate in multiple sclerosis patients with allergicrespiratory diseases. 44
Pregnancy And Fetal Outcomes After Paternal Exposure To Disease Modifying Drugs For Multiple Sclerosis (P4.157) 44
Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study 40
Correction to: Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study 38
SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose 36
Progressive multifocal leukoencephalopathy or severe multiple sclerosis relapse following COVID-19 vaccine: a diagnostic challenge 29
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis 25
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients 7
Totale 7.538
Categoria #
all - tutte 31.479
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.479


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021616 86 0 91 1 37 123 1 2 80 68 58 69
2021/2022357 2 4 6 57 11 11 16 34 32 7 54 123
2022/20231.321 104 152 72 158 143 272 81 93 171 17 29 29
2023/2024653 46 30 38 16 37 225 145 30 0 31 5 50
2024/20251.766 117 317 334 26 34 65 42 59 123 94 230 325
2025/2026138 138 0 0 0 0 0 0 0 0 0 0 0
Totale 7.538